BRGX BIOREGENX, INC.

Overview and Growth

BIOREGENX, INC. generated $1.85M of revenue in fiscal 2025, with net loss of $1.54M and an operating cash inflow of $38.97K. Revenue of $1.85M sets the scale for evaluating how effectively sales translated into profit and cash during the year. Compared with $2.34M in fiscal 2024, revenue decreased 20.8%, a top-line contraction that reduced operating scale. Diluted earnings per share were $0.00, translating the period’s attributable earnings into the amount reported for each diluted share. The diluted weighted-average share count was 959.71M, linking total earnings with the per-share result received by shareholders. The company employed $410.99K of total assets, the balance-sheet base supporting its current operating and cash-flow results. Revenue equaled 4.51x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

Gross profit was $1.50M, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. The gross-profit relationship equaled 81.1% of revenue, quantifying the portion retained before operating expenses were recognized. The company recorded an operating loss of $1.24M after the reported operating expense base. The operating loss equaled 67.1% of revenue, showing the scale of the operating deficit relative to sales. The bottom-line result was a net loss of $1.54M after operating, financing, tax, and other recognized items. Net margin was -83.2%, reflecting a loss equal to 83.2% of reported revenue. EBITDA was negative $1.17M, showing a deficit before interest, taxes, depreciation, and amortization. The loss-to-assets relationship was 375.6%, placing the bottom-line deficit against the company’s resource base. Compared with a $23.05M net loss in fiscal 2024, the current loss improved to $1.54M.

Liquidity and Capital Structure

Total assets were $410.99K, supported by $4.95M of liabilities and -$4.54M of shareholder equity. The company reported negative equity of -$4.54M, a capital deficit that reduces its ability to absorb losses through book equity. Current assets were $251.26K against $4.07M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. Current assets covered only 0.06x of current liabilities, so current liabilities exceeded current assets at period end. Reported cash and equivalents were $69.38K, separating immediately recognizable cash resources from the rest of the current-asset base. Measured only with cash and equivalents, coverage of current liabilities was 1.7%, excluding receivables and other current assets. Borrowings totaled $1.19M, adding a fixed financing obligation alongside the company’s equity capital. Relative to total assets, debt measured 288.3%, showing how much of the asset base was matched by borrowing. The cash-to-assets relationship was 16.9%, comparing reported cash and equivalents with the full positive asset balance. Compared with $508.54K in fiscal 2024, the current asset base moved 19.2% and finished lower. Compared with $58.40K in fiscal 2024, the current cash balance moved 18.8% and finished higher.

Cash Flow and Earnings Quality

The company reported $38.97K of operating cash flow, a cash inflow that shows the cash generated by operations. Capital expenditures used $9.06K, identifying the reported investment outflow deducted from operating cash flow in the free-cash-flow calculation. Capital spending absorbed 23.2% of operating cash flow, quantifying the share of cash from operations directed to investment. The combination of operating cash flow and capital spending produced $29.91K of positive free cash flow for the period. Free cash flow represented 1.6% of revenue, linking post-investment cash generation with the company’s operating scale. The free-cash-flow-to-assets relationship was 7.3%, comparing post-investment cash with the balance-sheet asset base. Operations shifted from absorbing $324.15K in fiscal 2024 to generating $38.97K of cash.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.